Join to View Full Profile
9715 Burnet RdBldg 7. STE 200Austin, TX 78758
Phone+1 515-505-5500
Dr. Jurdi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Adham Jurdi is an oncologist in Austin, TX, practicing with Austin Cancer Center. He previously worked with SUNY Upstate Medical University and Syracuse VAMC. He has been in practice since 2013. He subspecializes in Gastrointestinal and Thoracic malignancies.
Education & Training
East Tennessee State University/Quillen College of MedicineFellowship, Medical Oncology, 2011 - 2013- East Tennessee State University/Quillen College of MedicineResidency, Internal Medicine, 2008 - 2011
Beirut Arab University Faculty of MedicineClass of 2006
Certifications & Licensure
TX State Medical License 2019 - 2025
NY State Medical License 2014 - 2023
VA State Medical License 2012 - 2016
Publications & Presentations
PubMed
- Circulating Tumor DNA Assessment to Predict Risk of Recurrence after Surgery in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Prospective Observ...Shogo Takei, Daisuke Kotani, George Laliotis, Kazuma Sato, Naoto Fujiwara
Annals of Surgery. 2025-03-21 - 1 citationsDetecting Early Recurrence With Circulating Tumor DNA in Stage I-III Biliary Tract Cancer After Curative Resection.James Yu, Aiwu Ruth He, Mahmoud Ouf, Rutika Mehta, Daniel A Anaya
JCO Precision Oncology. 2025-01-01 - Circulating Tumor DNA as a Prognostic Biomarker for Recurrence in Patients With Locoregional Esophagogastric Cancers With a Pathologic Complete Response.Eric Michael Lander, Vasily N Aushev, Brandon M Huffman, Diana Hanna, Punashi Dutta
JCO Precision Oncology. 2024-12-01
Press Mentions
Natera Announces Enrollment of First Patients in SAGITTARIUS: A Randomized, Phase III Clinical Trial in Colon CancerDecember 12th, 2024- New Signateratm MRD Data in Gastrointestinal Cancers to Be Presented at the ASCO GI Symposium 2023January 19th, 2023
- New Signatera™ MRD Data in Gastrointestinal Cancers to Be Presented at the ASCO GI Symposium 2023January 19th, 2023
- Join now to see all
Professional Memberships
- Member
Other Languages
- Arabic
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
